XML 64 R52.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Information    
Revenue $ 10,000  
Research and development expenses (34,915) $ (22,645)
General and administrative (12,415) (4,933)
Stock-based compensation (5,386) (947)
Net loss to common stockholders (33,573) (27,800)
Single Reportable Segment    
Segment Information    
Revenue 10,000  
General and administrative 8,610 4,397
Stock-based compensation 5,386 947
Other segment items (3,757) 222
Net loss to common stockholders $ (33,573) $ (27,800)
Other segment items, description Other segment items consist of other income (expense), net and income tax benefit (provision). Other income (expense), net consists of interest income and realized and unrealized gains and losses on foreign currency transactions Other segment items consist of other income (expense), net and income tax benefit (provision). Other income (expense), net consists of interest income and realized and unrealized gains and losses on foreign currency transactions
Single Reportable Segment | Obexelimab    
Segment Information    
Research and development expenses $ 23,491 $ 12,295
Single Reportable Segment | Other programs (ZB002 & ZB004)    
Segment Information    
Research and development expenses 203 894
Single Reportable Segment | Partnered regional programs (ZB001 & ZB005)    
Segment Information    
Research and development expenses 99 1,588
Single Reportable Segment | Unallocated    
Segment Information    
Research and development expenses $ 9,541 $ 7,457